{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-070378","form_type":"8-K","ticker":"NTRB","cik":"0001676047","company_name":"NutriBand Inc.","filed_at":"2026-06-22T12:02:58+00:00","discovered_at":"2026-06-22T12:05:00.230815+00:00","generated_at":"2026-06-22T12:05:11.829572+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nutriband enters amended $5M credit line at 7% interest for AVERSA Fentanyl","bullets":["$5M credit line facility amended as of June 1, 2026, replacing prior $5M facility expiring July 2026.","Interest at 7% per annum; no conversion rights for lender into common stock.","Proceeds for commercialization of AVERSA Fentanyl, including FDA submission and manufacturing costs with Kindeva Drug Delivery.","Maturity date July 1, 2029; advances allowed only after commencement of NDA-related work with Kindeva."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-070378","json":"https://secwatch.observer/filing/0001213900-26-070378.json","markdown":"https://secwatch.observer/filing/0001213900-26-070378.md","text":"https://secwatch.observer/filing/0001213900-26-070378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676047/000121390026070378/0001213900-26-070378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676047/000121390026070378/ea0295410-8k_nutriband.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:05:11.829572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"363bdb5e3656cb095ea9fc0d9eb017b965ea2c26","claim":"NutriBand Inc. amended a credit facility valued at $5,000,000 (effective 2026-06-01).","evidence_excerpt":"The Company on June 1, 2026 entered into an amended three-year $5,000,000 credit line facility (replacing the $5,000,000 facility (that we had entered into on March 19, 2023, and scheduled to expire July 13, 2026), drawdowns under which bear interest at the rate of 7% per annum.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676047/000121390026070378/0001213900-26-070378-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Value","value":"$5,000,000"},{"label":"Effective","value":"2026-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}